Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
British Journal of Sports Medicine
|
June 16, 2017
Emergency response facilities including primary and secondary prevention strategies across 79 professional football clubs in England
Aneil Malhotra, Harshil Dhutia, Sabiha Gati, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
May 17, 2023
A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator
Jonas M den Heijer, Annelieke C Kruithof, Matthijs Moerland, et al.
JACC. Cardiooncology
|
January 6, 2022
Clinical, Echocardiographic, and Biomarker Associations With Impaired Cardiorespiratory Fitness Early After HER2-Targeted Breast Cancer Therapy
Alis Bonsignore, Thomas H Marwick, Scott C Adams, et al.
JACC. Cardiooncology
|
October 10, 2022
Self-Reported Physical Activity, QoL, Cardiac Function, and Cardiorespiratory Fitness in Women With HER2+ Breast Cancer
Serena S Peck, Maryam Esmaeilzadeh, Kate Rankin, et al.
Journal of Medicinal Chemistry
|
December 17, 2014
Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers
Bernard Barlaam, Sabina Cosulich, Sébastien Degorce, et al.
British Journal of Clinical Pharmacology
|
February 12, 2021
A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator
Jonas M den Heijer, Annelieke C Kruithof, Guido van Amerongen, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 11, 2008
The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing
Clifford D Jones, David M Andrews, Andrew J Barker, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 26, 2008
Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors
Malcolm Anderson, David M Andrews, Andy J Barker, et al.
Cancer Research
|
May 19, 2005
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer
Stephen R Wedge, Jane Kendrew, Laurent F Hennequin, et al.
Science Translational Medicine
|
February 12, 2016
Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo
Susan Ashton, Young Ho Song, Jim Nolan, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
British Journal of Sports Medicine
|
June 16, 2017
Emergency response facilities including primary and secondary prevention strategies across 79 professional football clubs in England
Aneil Malhotra, Harshil Dhutia, Sabiha Gati, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
May 17, 2023
A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator
Jonas M den Heijer, Annelieke C Kruithof, Matthijs Moerland, et al.
JACC. Cardiooncology
|
January 6, 2022
Clinical, Echocardiographic, and Biomarker Associations With Impaired Cardiorespiratory Fitness Early After HER2-Targeted Breast Cancer Therapy
Alis Bonsignore, Thomas H Marwick, Scott C Adams, et al.
JACC. Cardiooncology
|
October 10, 2022
Self-Reported Physical Activity, QoL, Cardiac Function, and Cardiorespiratory Fitness in Women With HER2+ Breast Cancer
Serena S Peck, Maryam Esmaeilzadeh, Kate Rankin, et al.
Journal of Medicinal Chemistry
|
December 17, 2014
Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers
Bernard Barlaam, Sabina Cosulich, Sébastien Degorce, et al.
British Journal of Clinical Pharmacology
|
February 12, 2021
A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator
Jonas M den Heijer, Annelieke C Kruithof, Guido van Amerongen, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 11, 2008
The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing
Clifford D Jones, David M Andrews, Andrew J Barker, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 26, 2008
Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors
Malcolm Anderson, David M Andrews, Andy J Barker, et al.
Cancer Research
|
May 19, 2005
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer
Stephen R Wedge, Jane Kendrew, Laurent F Hennequin, et al.
Science Translational Medicine
|
February 12, 2016
Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo
Susan Ashton, Young Ho Song, Jim Nolan, et al.
Page
of 5